Category: Press Release

March 31, 2007 — ITHACA, N.Y., March 31, 2007 – Advion BioSciences, Inc., a leader in the life science analytical industry, announced it has completed the analysis of samples associated with the recent pet food recall. This work was done in collaboration with Cornell’s College of Veterinary Medicine, the FDA and other North American selected laboratories. Advion BioSciences was asked to act as a reference laboratory to support Cornell University’s efforts.

Aminopterin, a commonly used rat poison, was suspected of being present in certain components of the pet food. The company coordinated the efforts of its two business divisions, BioSystems and BioServices, to utilize the scientific talents at its disposal. Under the direction and coordination of Dr. Jack Henion, Chief Scientific Officer and co-founder of the company, the results were completed within 72 hours and shared with Cornell University’s College of Veterinary Medicine. Advion’s scope of work was viewed as important for the scientific mission to identify the unknown toxin in the pet food ingredients and helped form the basis of conclusions shared with the global media on March 30th. Advion confirmed the presence of melamine in wheat gluten using sophisticated commercial analytical equipment in conjunction with Advion’s systems which provided additional valuable data for the identification of melamine. Advion detected no evidence for aminopterin in any of the gluten samples.

Advion BioServices is one of the largest and most respected independent commercial bioanalytical laboratories in the world, serving the pharmaceutical and biopharmaceutical industry.

Given the broad global interest in the pet food recall, the company is strongly considering broadening its business model to analyze melamine, aminopterin and other analytes in pet food samples and pet biological samples (including blood or urine) for a fee basis. This decision will be made shortly and posted on the company’s website www.advion.com.

About Advion:
Founded in 1993, Advion BioSciences, Inc. are pioneers in bioanalytical services and innovators of products for the life science industry.

For Advion:
Amy Boardman
Advion
Manager of Corporate Marketing Communications
607.266.9162
aboardman@advion.com

March 31, 2007 — ITHACA, N.Y., March 31, 2007 As previously reported, Advion BioSciences, innovators in products for the life science industry, was called upon to collaborate with Cornell’s College of Veterinary Medicine, the FDA and other laboratories across the country to assist in analyzing samples associated with the recent pet food recall.

Following reports in the national news of a chemical named aminopterin being present in the gluten material used in components of the pet food, Advion sought to confirm the presence of aminopterin as well as identify any other foreign substances that may be present in the gluten materials. Advions efforts were directed by Dr. Jack Henion, Chief Scientific Officer. Advion’s BioServices division is a well-respected bioanalytical laboratory serving the pharmaceutical industry. Scientists from the bioanalytical laboratory worked closely with the TriVersa NanoMate application scientists to analyze the samples using LC/MS/MS.

Advion’s TriVersa Nanomate readily confirmed aminopterin in positive control standards at low part per million levels, but detected no evidence for aminopterin in any of the gluten samples reportedly associated with the pet food poisonings. During the course of these experiments, the FDA reported the presence of another chemical in the gluten called melamine. The TriVersa NanoMate system readily detected and confirmed this chemical. More information regarding this Advion product can be found at www.advion.com

About Advion:
Founded in 1993, and known as a leader in the industry, Advion BioSciences, Inc. are pioneers in bioanalytical services and innovators of products for the life science industry.

For Advion:
Amy Boardman
Manager of Corporate Marketing Communications
607.266.9162 ext. 314
aboardman@advion.com

March, 2007– Effective April 23, 2007, Advion BioSciences, Inc. and it’s subsidiaries, Advion BioServices and Advion BioSystems will relocate to one location at

19 Brown Road
Ithaca, NY 14850

The new building has been built to accomodate Advion’s growing business and to provide a more efficient work environment to serve its clients and customers.

All deliveries scheduled to arrive on or after April 23rd should be directed to the new address. Phone numbers and email addresses will remain the same. If you have any questions, please contact Advion.

December 11, 2006 – Advion BioServices, a specialist in method development and validation of proprietary methods, also has a variety of validated non-proprietary LC/MS/MS methods available including the analysis of Methotrexate and 7-Hydroxymethotrexate to support clinical studies.

Methotrexate was originally developed to aid in the treatment of cancer, but has since been found to help treat several autoimmune diseases including psoriasis and rheumatoid arthritis. While Methotrexate is a commonly prescribed and used drug, Advion is one of the few bioanalytical laboratories which has a validated LC/MS/MS method for both Methotrexate and the 7-Hydroxymethotrexate metabolite. The Advion assays use solid-phase extraction to isolate the analytes and stable-labeled standards are available for both metabolites .The Advion assays are established for analysis of human plasma, urine and plasma samples.

Non-proprietary established validated methods offer a cost-effective and timely solution for clients with drug-drug interaction (DDI) or comparison studies with established therapeutic compounds. Advion is happy to partner with new and existing customers to develop non-proprietary assays which have value to the pharmaceutical industry.
For a complete list of Advion’s non-proprietary list of validated assay visit here

11-16-2006 — Ithaca, NY, November 16, 2006 – Advion BioSciences, Inc. today announced a collaboration between its subsidiary, Advion BioSystems, Inc., and Waters Corporation to integrate the Advion TriVersa™ NanoMate® with the Waters® Synapt High Definition MS™ (HDMS) system. This is the most recent collaboration since the two companies began working together in 2003.

Launched this year, the Waters Synapt™ HDMS System enables researchers to analyze samples which are differentiated by size and shape, as well as mass. This capability is enhanced by the Advion TriVersa NanoMate which provides long, stable spray times and ease of use. The joint effort allows both companies to create a simpler and easier to use combined platform for their customers. Additionally, the existing co-marketing agreement allows for the co-promotion of the integrated platform at industry events.

This system is ideally suited for proteomics applications, especially noncovalent interaction research or any research requiring more information from complex samples. Early successes have already been realized with commercial placements.

“There was no question that Advion should collaborate with Waters on this project. The Synapt HDMS and the TriVersa NanoMate are an ideal match in capabilities. The strength and value of these systems, offered to proteomics researchers looking for higher quality data, is exceptional,” commented Dr. Jack Henion, Chief Scientific Officer and Chairman of Advion. Dr. Henion also added, “As mass spectrometers change and grow to meet researchers’ needs, it is important for Advion’s chip-based technology to change and grow with them. This joint venture shows a commitment by Advion to continue enhancing its technology and adapting to meet the needs of its customers.”

About Advion BioSciences, Inc.
Advion BioSciences, Inc. was founded in 1993 based on the novel techniques developed within the Cornell University laboratory of Dr. Jack Henion, a leading researcher in the field of LC/MS. Advion is a pioneer in bioanalytical services and innovators of products for the life science industry with customers in major pharmaceutical companies, government life science research agencies and universities. For more information about Advion visit www.advion.com

About Waters Corporation
Waters Corporation holds worldwide leading positions in three complementary analytical technologies – liquid chromatography, mass spectrometry and thermal analysis. These markets account for approximately $5.0 billion of the overall $20 – 25 billion analytical instrument market. For more information about Waters visit www.waters.com

For Advion:
Advion BioSciences, Inc.
Amy Boardman
Manager of Corporate Marketing Communications
607.266.9162 x314
aboardman@advion.com

For Waters:
Brian J. Murphy
Corporate Communications
508.482.2614
brian_j_murphy@water.com

November 14, 2006– Advion BioSciences announced today an update to the joint marketing agreement between Thermo Fisher Scientific and Advion BioSystems, Inc. The expanded agreement now includes Thermo Scientific’s recently released award winning LTQ Orbitrap hybrid mass spectrometer in combination with the Advion TriVersa™ NanoMate(R) system. Originated in 2003, the joint marketing agreement was renewed in June 2005 and further expanded in 2006. The agreement allows for co-promotion of each company’s instrumentation and demonstration facility instrumentation investments. To date the agreement has resulted in numerous joint sales. The addition of the highly successful LTQ Orbitrap to the agreement is expected to add further unit sales. The combination of the TriVersa NanoMate with the Thermo Scientific line of mass spectrometers, including the new LTQ Orbitrap, is very powerful for a range of research areas including top-down proteomics, protein characterization and biomarker discovery. This update shows a commitment by both parties to continue a very successful partnership.

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

July 31, 2006 — ITHACA, N.Y., July 31, 2006 — Advion BioSciences, Inc., a leading provider of Bioanalytical services and products to the pharmaceutical and biotech industry, today announced that it has appointed Mr. Stephen Guyan as Director of Sales and Marketing to the company’s BioServices subsidiary, effective July 31, 2006.

“Mr. Guyan brings a wide range of experience to Advion including instrumentation and applications development, laboratory management, and the sales and marketing of bioanalytical services to pharmaceutical and biotechnology clients,” said Tom Kurz, President of Advion BioServices, “He is well respected in the industry and his experience will provide tremendous strength to Advion BioServices’ business development efforts. We are very excited to have Steve join the Advion team.”

Mr. Guyan has more than 20 years experience in sales and marketing of bioanalytical services and laboratory instrumentation. Most recently, he was responsible for managing the Bioanalytical Group at Charles River Laboratories, a drug discovery and development solutions provider in Worcester, MA. Prior to that, Mr. Guyan served as VP Sales & Marketing at Taylor Technology and was responsible for the Sales and Marketing of a newly formed bioanalytical laboratory division at Triangle Laboratories, Inc. At both Triangle Laboratories and Taylor Technology, he managed client contacts, the Sales & Marketing strategy and budget, trade shows and advertising, and marketing intelligence, and organized scientific conferences. He worked for VG in England as a Demonstration Chemist for their mass spectrometry products before moving to the United States to join Triangle Laboratories, Inc. He holds a Masters of Science degree in Chemistry from the University of Manchester in England.

“Advion has earned the reputation of delivering the highest standard of scientific and customer service in the analytical contract industry,” said Guyan. “I am extremely proud to be a part of this excellent organization.”

About Advion:
Founded in 1993 and based in Ithaca, NY by Dr. Jack Henion and Mr. Thomas Kurz, Advion BioSciences, Inc. is recognized as a world leader in Bioanalytical services, Systems and Consumables for the Life Science industry. Advion BioServices delivers scientific excellence with unparalleled service to the pharmaceutical industry worldwide. In addition to customized LC/MS/MS method development, validation, and sample analysis services, Advion BioServices also offers Sample Management, Metabolism, Biomarker, and Discovery services.

Advion BioSystems’ proprietary instrument products employ novel chip-based nano-electrospray technology to improve the analytical information generated from conventional commercially available Mass Spectrometry systems. This combination provides enhanced analyses of proteins, post-translational modifications, biomarkers, lipids, and metabolites. For more information about Advion, visit www.advion.com.

For Advion:
Amy Boardman
Manager of Corporate Marketing Communications
Advion BioSciences, Inc.
607.266.0665 ext. 314
aboardman@advion.com

July 6, 2006 — ITHACA, N.Y., July 6, 2006 — Advion BioSciences, Inc., a leading provider of Bioanalytical services and products to the pharmaceutical and biotech industry, today broke ground on its new and expanded global headquarters and operating facility. The facility will dramatically expand the company’s laboratory space, provide for co-location with the Systems and Consumables business and accommodate continued growth in the future. The facility is scheduled for completion in May 2007, and is currently under construction at 19 Brown Road in the Cornell Business and Technology Park (CBTP), adjacent to the Tompkins County Airport.

“This is an exciting period for the company,” said Dave Patteson, Advion President and CEO. “Our growth has been notable and we needed a way to increase our capacity and yet be more efficient in a build-to-suit structure. The new HQ is expected to yield a much better customer and employee atmosphere, have better workflow and allow the company to function with better communications, internally and externally. The support we have received from the community, Cornell and local stakeholders has been exemplary.”

John Majeroni, Director of Real Estate at Cornell commented: “Advion is the company that every community dreams of—great paying jobs, strong ties to the community, a technology-based, service-oriented business that can thrive in a small but highly educated city. The company has grown from its two founders to employ more than 140 persons, and this new facility will enable them to grow even more. There are many links between Advion and Cornell University and we here at Cornell are excited that there is now one more.”

Founded in 1993 and based in Ithaca, NY by Dr. Jack Henion and Mr. Thomas Kurz, Advion BioSciences, Inc. is recognized as a world leader in Bioanalytical services, Systems and Consumables for the Life Science industry. Advion BioServices delivers scientific excellence with unparalleled service to the pharmaceutical industry worldwide. In addition to customized LC/MS/MS method development, validation, and sample analysis services, Advion BioServices also offers Sample Management, Metabolism, Biomarker, and Discovery services.

Advion BioSystems’ proprietary instrument products employ novel chip-based nano-electrospray technology to improve the analytical information generated from conventional commercially available Mass Spectrometry systems. This combination provides enhanced analyses of proteins, post-translational modifications, biomarkers, lipids, and metabolites.

For Advion:
Ms. Amy Boardman
Marketing Manager
607.266.9162 ext.314
aboardman@advion.com

March 2, 2006 — ITHACA, N.Y., March 2, 2006 — Advion BioSciences, Inc., today announced the appointment of Mr. David Patteson as President and Chief Executive Officer to take effect April 3, 2006. Patteson brings to Advion over twenty years of leadership experience in managing global businesses that develop and sell products to the analytical and organic chemistry market. He will be responsible for overseeing the business leadership, growth and strategic development of both the Advion BioServices and Advion BioSystems business units. Dr. Jack Henion, co-founder, and the current President, CEO and Chairman of Advion BioSciences will become Chief Scientific Officer and remain Chairman of the Board of Directors. Mr. Thomas Kurz will continue to serve as President of Advion BioServices.

“Dave Patteson possesses the integrity, business experience and leadership skills to take Advion to new heights of success as its President and CEO. I am very excited about working with Dave as we continue growing Advion’s core business units while also seeking new opportunities for growth. With Dave on board, I will now focus on important scientific and business development opportunities for both of the Advion subsidiaries,” said Henion.

Patteson comes to Advion after spending nearly eight years with Biotage, where he most recently held the position of President and COO, Biotage, LLC, President of the Discovery Chemistry Group and was a member of the Executive Committee of the corporate parent Biotage AB. From 1998 to 2006, he grew the Biotage life science business significantly, acquired and integrated a number of companies, and moved the group to profitability. From 1994-1998, Patteson managed and grew the diverse Process Analytical and Field Measurement Controls business of The Foxboro Company.

Mr. Patteson commented, “I am enthusiastic about joining Advion Biosciences as their new CEO. The company has an ideal mix of talented people and compelling technology that produces high-value products and services. The shareholder base is extraordinarily committed to the company’s success and growth. And I relish the chance to work with an industry legend such as Jack Henion. I believe that with the right focus, we can take the company to the next stage of global development”.

Founded in 1993 by Dr. Jack Henion and Mr. Thomas Kurz, Advion BioSciences, Inc. is a privately held company with three wholly owned subsidiaries – Advion BioServices, Inc., Advion BioSystems, Inc. and Advion BioSciences, Ltd. Recognized as a world leader in LC/MS/MS bioanalytical services, Advion BioServices delivers scientific excellence with unparalleled service to the pharmaceutical industry worldwide. Included among its clients are 14 of the top 16 global pharmaceutical companies. In addition to customized LC/MS/MS method development, validation, and sample analysis services, Advion BioServices also offers Sample Management, Metabolism, Biomarker, and Discovery services.

Initially commercialized in 2002, Advion BioSystems’ proprietary instrument products employ novel chip-based technology to improve the analytical information generated from electrospray MS. Advion’s most recent product, the TriVersa NanoMate, combines the strengths of LC/MS, fraction collection, and chip-based infusion in one system. This combination provides greater information content for mass spectrometric analyses including protein identification, post-translational modifications, biomarker discovery, lipidomics, and metabolite identification. For more information about Advion, visit www.advion.com.

June 6, 2005 — (Ithaca, NY – June 6, 2005) – Advion Inc., of Ithaca, N.Y., a developer of chip-based products designed to boost the sensitivity, data quality and sample throughput for mass spectrometers today introduced its TriVersa NanoMate System at the 53rd annual meeting of the American Society for Mass Spectrometry (ASMS), held in San Antonio, TX, June fifth through June nineth. Founded in 1993, the privately held company has many top academic institutions, biotechnology companies, and pharmaceutical companies as clients.

Scheduled for commercial availability in Q3 2005, TriVersa NanoMate is the first system of its kind to integrate LC/MS, fraction collection and chip-based infusion in one platform. TriVersa gives proteomics and small molecule researchers the ability to obtain greater than 10 times more information from their sample. The system speeds the discovery process by allowing extra time to analyze complex components not easily characterized on a chromatographic time scale.

The versatility of the system allows interrogation of samples using on-line LC/MS and infusion of LC fractions. The system is compatible with LC, micro and nanoLC for low concentration samples. Additionally, TriVersa NanoMate works with most API mass spectrometers.

For Advion:
Laura Cima
Manager of Global Marketing
Advion
15 Catherwood Road
Ithaca, NY 14850
607-266-0665 x201
lcima@advion.com